Announcement
1
VOL. 62, No. 3, MARCH 2001 Announcement The Charles R. Ream, MD, Award for Excellence-2000 The Editorial Board members of Current Therapeutic Research@ have chosen to give the first Charles R. Ream, MD, Award for Excellence to Benjamin Volovitz, Elida Dueiias-Meza, Danuta A. Chmielewska-Szewczyk, Lajos Kosa, Natalia Astafieva, CCsar Villaran, Carlos Pinacho-Daza, Martin0 Laurenzi, Jay Jasan, Joris Menten, and Jonathan Leff, for their paper “Comparison of Oral Mon- telukast and Inhaled Cromolyn with Respect to Preference, Satisfaction, and Adherence: A Multicenter, Randomized, Open-Label, Crossover Study in Chil- dren with Mild to Moderate Persistent Asthma” (Cur-r Ther Res Clin Exp. 2000; 61:490-506). Their paper was chosen for several reasons. The authors, investigators, and patients were truly international, representing 17 countries on 5 continents. The authors studied a patient management question-choice of medication- that may alter prescribing patterns. In addition, they studied asthma, a serious and possibly life-threatening condition that has become more prevalent in re- cent years. Like so many questions regarding patients and their medications, the analysis uses “soft” end points, such as compliance and satisfaction regard- ing the ease of administration and taste of the formulation. In pediatrics, these problems are compounded because parents and caregivers also have a role. Thus, the investigators had to examine 2 levels of compliance and satisfaction to determine preferences. The assessment instruments were tested and modi- fied before the study began. More important, the authors included their ques- tionnaire as an appendix so that readers could replicate the study, analyze the questionnaire, and perhaps improve it. The investigators chose the less com- mon crossover design for their study, and the trial used an open-label design by necessity-factors that could have reduced the likelihood of acceptance of the paper. Finally, the authors discussed potential weaknesses of their study and refuted some of them. This type of analysis exemplifies the manner in which clinical trials should be reported. We are grateful to the Editorial Board members, who provided dispassion- ate, reasoned judgment of the papers published throughout the year, and to Jeffrey L. Blumer, PhD, MD, Section Editor of Trials in Pediatric Populations, the section in which the award-winning paper appeared. The Editorial Board and staff of Current Therapeutic Research@ thank all of the journal’s contributing authors and offer congratulations to our first award winners! Michael Weintraub, MD Editor-in-Chief 179
-
Upload
michael-weintraub -
Category
Documents
-
view
215 -
download
1
Transcript of Announcement
VOL. 62, No. 3, MARCH 2001
Announcement
The Charles R. Ream, MD, Award for Excellence-2000
The Editorial Board members of Current Therapeutic Research@ have chosen to give the first Charles R. Ream, MD, Award for Excellence to Benjamin Volovitz, Elida Dueiias-Meza, Danuta A. Chmielewska-Szewczyk, Lajos Kosa, Natalia Astafieva, CCsar Villaran, Carlos Pinacho-Daza, Martin0 Laurenzi, Jay Jasan, Joris Menten, and Jonathan Leff, for their paper “Comparison of Oral Mon- telukast and Inhaled Cromolyn with Respect to Preference, Satisfaction, and Adherence: A Multicenter, Randomized, Open-Label, Crossover Study in Chil- dren with Mild to Moderate Persistent Asthma” (Cur-r Ther Res Clin Exp. 2000; 61:490-506).
Their paper was chosen for several reasons. The authors, investigators, and patients were truly international, representing 17 countries on 5 continents. The authors studied a patient management question-choice of medication- that may alter prescribing patterns. In addition, they studied asthma, a serious and possibly life-threatening condition that has become more prevalent in re- cent years. Like so many questions regarding patients and their medications, the analysis uses “soft” end points, such as compliance and satisfaction regard- ing the ease of administration and taste of the formulation. In pediatrics, these problems are compounded because parents and caregivers also have a role. Thus, the investigators had to examine 2 levels of compliance and satisfaction to determine preferences. The assessment instruments were tested and modi- fied before the study began. More important, the authors included their ques- tionnaire as an appendix so that readers could replicate the study, analyze the questionnaire, and perhaps improve it. The investigators chose the less com- mon crossover design for their study, and the trial used an open-label design by necessity-factors that could have reduced the likelihood of acceptance of the paper. Finally, the authors discussed potential weaknesses of their study and refuted some of them. This type of analysis exemplifies the manner in which clinical trials should be reported.
We are grateful to the Editorial Board members, who provided dispassion- ate, reasoned judgment of the papers published throughout the year, and to Jeffrey L. Blumer, PhD, MD, Section Editor of Trials in Pediatric Populations, the section in which the award-winning paper appeared. The Editorial Board and staff of Current Therapeutic Research@ thank all of the journal’s contributing authors and offer congratulations to our first award winners!
Michael Weintraub, MD Editor-in-Chief
179
